Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Antitumor agent
Public University Corporation Nagoya City University
June 14, 2018 - N°20180163208

This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a tug1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression ...
Diagnosis and treatment of cancer using anti-itm2a antibody
Chugai Seiyaku Kabushiki Kaisha
June 07, 2018 - N°20180155438

Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
Organic compositions to treat kras-related diseases
Arrowhead Pharmaceuticals, Inc.
June 07, 2018 - N°20180153919

The present disclosure relates to rnai agents useful in methods of treating kras-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
Morphosys Ag
June 07, 2018 - N°20180153892

The present disclosure describes a pharmaceutical combination of an anti-cd19 antibody and a bruton's tyrosine kinase (btk) inhibitor for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.. .
Methods of using bispecific cd33 and cd3 binding proteins
Amphivena Therapeutics, Inc.
May 31, 2018 - N°20180148507

Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
T cell receptor-like antibodies specific for a prame peptide
Eureka Therapeutics, Inc.
May 31, 2018 - N°20180148503

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to preferentially expressed antigen of melanoma (prame), including humanized, chimeric and fully human antibodies against prame, antibody fragments (e.g., scfv, fab and f(ab)2), chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a prame peptide/hla class i molecule complex.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods, reagents and kits for detecting minimal residual disease
Erasmus University Medical Center Rotterdam
May 24, 2018 - N°20180140664

The invention relates to the field of minimal residual disease (mrd) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as b-cell precursor acute lymphoblastic leukemia (bcp-all), b-cell chronic lymphocytic leukemia (b-cll), and multiple myeloma (mm). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, ...
Liquid biopsy detection of leukemia using closed-loop microfluidics
Massachusetts Institute Of Technology
May 17, 2018 - N°20180136210

This invention describes a one-step technique for the simultaneous label-free detection and concentration of blast cells from a blood sample. Enrichment of blast cells is achieved using a closed loop microfluidics system, allowing continuous removal of waste and non-target cells to generate concentrated samples of high purity without the need for specific targeting of proteins by antibodies.
Cd123 specific multi-chain chimeric antigen receptor
Cellectis
May 17, 2018 - N°20180134795

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cd123. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cd123.
Antibody agents specific for human cd19 and uses thereof
Eureka Therapeutics, Inc.
May 17, 2018 - N°20180134787

Described herein are human antibody agents and multi-specific binding agents that specifically bind human cd 19, in particular, native human cd 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by cd 19 expression, in particular, b cell lymphomas and leukemias..
Compounds for treating rac-gtpase mediated disorder
The Children`s Medical Center Corporation
May 17, 2018 - N°20180134694

This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of a rac-gtpase mediated disorder (e.g., acute lymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds for treating a rac-gtpase mediated disorder.. .
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using ...
Dana-farber Cancer Institute, Inc.
May 17, 2018 - N°20180133297

The disclosure features, inter alia, immunogenic xbp1-, cd138-, and cs1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., ...
Fructose analogs and their combinations as anti-cancer agents
May 17, 2018 - N°20180133192

The present invention provides a fructose analogue and a composition thereof which can be used for cancer treatment, has a targeting effect and has little effect on normal cells, particularly when used in the treatment of acute myeloid leukemia (‘aml’) and pancreatic cancer and other types of cancer having similar metabolic characteristics. In the present invention, the fructose ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapy for leukemia
Children's Hospital Medical Center
May 10, 2018 - N°20180125799

A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-fos, (b) an inhibitor of dusp-1, and (c) an inhibitor of bcr-abl tyrosine kinase.
Methods for treating acute myeloid leukemia and nanoparticle complexes of mir-22 utilized therein
University Of Cincinnati
May 03, 2018 - N°20180119150

Compositions and methods for treating acute myeloid leukemia (aml) based on upregulating expression of microrna-22 (mir-22), and a nanoparticle delivery system that utilizes flt3-functionalized polyamidoamine (pamam) dendromirs for targeted delivery of mir-22 and/or agents that upregulate expression of mir-22 to aml cells.. .
Alpha-amino pateamine a derivatives and methods for treating chronic lymphocytic leukemia
The Texas A&m University System
May 03, 2018 - N°20180118764

Pateamine a derivatives and pharmaceutical compositions that include the derivatives. The pateamine a derivatives are α-amino pateamine a derivatives that lack the c5-methyl group of pateamine a..
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
May 03, 2018 - N°20180118720

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Intramarrow injection/infusion and aspiration needle and method
May 03, 2018 - N°20180117262

A method and apparatus for injecting supportive and therapeutic agents into bone marrow. During conventional chemotherapy for leukemia, lymphoma, multiple myeloma and other bone related diseases, chemotherapeutic agents are typically injected intravenously.
Composition for inhibiting growth or proliferation of chronic myelogenous leukemia cancer stem cells, and screening ...
Hiroshima University
May 03, 2018 - N°20180117057

Provided are a composition for inhibiting growth or proliferation of chronic myelogenous leukemia (cml) cancer stem cells, a pharmaceutical composition for preventing or treating cml, a method for preventing or treating cml, and a method of screening for a growth or proliferation inhibitor of cml cancer stem cells by blocking nutrient signaling in cml cancer stem cells.. .
Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells
Nk-1 Ip Limited
May 03, 2018 - N°20180117027

The invention relates to the use of substance p antagonists and, in particular, the use of non-peptidic nk1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human hodgkin's lymphoma km-h2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human burkitt's lymphoma, human lung carcinoma, human ewing's sarcoma, human glioma and human osteosarcoma.. .
New biomarker for outcome in aml
Centre Antional De La Recherche Scientifique (cnrs)
April 19, 2018 - N°20180105882

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (aml) comprising i) determining the frequency of jam-c expressing lscs in a sample obtained from the patient ii) comparing the frequency determined at step i) with its predetermined reference value and iii) providing a good prognosis when the frequency determined ...
Loading